Coherus Q2 2026 net loss narrows to $33.3M; LOQTORZI revenue up 37% YoY to $13.6M

Coherus Oncology, Inc.

LOQTORZI net revenue $13.6M in Q2 2026, up 37% YoY from $10.0M and 15% sequentially from $11.8M.
GAAP net loss from continuing ops $33.3M ($0.22 diluted EPS) vs $44.9M ($0.39) in Q2 2025.
Non-GAAP net loss $30.1M ($0.19) vs $39.0M ($0.34) in prior year; total net revenue $14.3M.
R&D expenses fell to $21.4M from $26.3M; SG&A fell to $21.0M from $26.0M on cost reductions.
Pipeline: tagmokitug and casdozokitug trials enrolling; initial data readouts expected 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.